Interesting announcement by Argenica (AGN) today: they are examining a drug to reduce neurodegeneration after stroke and have just received a grant (CRC-P) to examine their drug in TBI with Curtin University and University of Adelaide.
I suspect that, if Invex is going to examine another indication, it'll be via this mechanism. I reckon they've submitted applications for funding in the UK to examine the drug in stroke or TBI (via Prof. Sinclair). Hopefully we see an announcement like the above in 2023 for IXC!
Fundamental Analysis Discussion Only (IXC Thread), page-10
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable